Related Experiment Videos
Merbarone: an antitumor agent entering clinical trials
A Glover1, H G Chun, L M Kleinman
1Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD.
Investigational New Drugs
|January 1, 1987
Summary
Merbarone shows anti-cancer activity, with effectiveness depending on administration schedule. Further clinical trials are needed to determine optimal dosing and understand its toxicity, particularly concerning saturable clearance mechanisms.
Area of Science:
- Oncology
- Pharmacology
- Toxicology
Background:
- Merbarone demonstrated anti-cancer effects against specific leukemias and sarcomas in preclinical models.
- Its efficacy is influenced by the duration of administration, suggesting schedule-dependency.
Purpose of the Study:
- To investigate the anti-cancer activity and mechanism of action of merbarone.
- To evaluate the pharmacokinetic and toxicological profile of merbarone in preclinical species and early human trials.
Main Methods:
- Preclinical studies assessed anti-cancer activity, DNA damage induction, and pharmacokinetics in rats, mice, and dogs.
- Phase I clinical trials were initiated to evaluate safety and pharmacokinetics using a continuous intravenous infusion schedule.
Main Results:
- Merbarone induces DNA single-strand breaks without direct DNA binding.
- Pharmacokinetic studies in dogs suggest saturable clearance mechanisms, with hydroxylation and glucuronidation as metabolic pathways.
- Preclinical toxicology identified lymphoid organs, bone marrow, GI tract, and kidneys as primary targets, with reversible CNS effects observed.
Conclusions:
- Merbarone's anti-cancer activity is schedule-dependent, and its mechanism involves DNA damage.
- Saturable clearance mechanisms may impact merbarone toxicity in humans, necessitating careful consideration of infusion rates.
- Phase I trial data are critical for optimizing merbarone's clinical development and therapeutic scheduling.